0000950170-24-024913.txt : 20240304 0000950170-24-024913.hdr.sgml : 20240304 20240304171823 ACCESSION NUMBER: 0000950170-24-024913 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240301 FILED AS OF DATE: 20240304 DATE AS OF CHANGE: 20240304 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Keson-Brookes Maiken CENTRAL INDEX KEY: 0001693805 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41837 FILM NUMBER: 24715620 MAIL ADDRESS: STREET 1: 35 OAK HILL ROAD CITY: FAYVILLE STATE: MA ZIP: 01745 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Mural Oncology plc CENTRAL INDEX KEY: 0001971543 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: L2 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 10 EARLSFORT TERRACE CITY: DUBLIN 2 STATE: L2 ZIP: D02 T380 BUSINESS PHONE: 353 1 905 8020 MAIL ADDRESS: STREET 1: 10 EARLSFORT TERRACE CITY: DUBLIN 2 STATE: L2 ZIP: D02 T380 FORMER COMPANY: FORMER CONFORMED NAME: Mural Oncology Ltd DATE OF NAME CHANGE: 20230403 FORMER COMPANY: FORMER CONFORMED NAME: Pistachiovale Ltd DATE OF NAME CHANGE: 20230329 4 1 ownership.xml 4 X0508 4 2024-03-01 0001971543 Mural Oncology plc MURA 0001693805 Keson-Brookes Maiken C/O MURAL ONCOLOGY PLC 10 EARLSFORT TERRACE DUBLIN 2 L2 D02 T380 IRELAND false true false false See Remarks false Ordinary Shares 2024-03-01 4 A false 16800 0.00 A 46007 D Stock Option (right to buy) 5.39 2024-03-01 4 A false 31200 0.00 A 2034-02-28 Ordinary Shares 31200 31200 D Consists of ordinary shares issuable under 16,800 restricted stock units ("RSUs"). Each RSU represents the right to receive one ordinary share upon vesting. The RSUs are scheduled to vest with respect to 25% of the underlying ordinary shares on each of the first four anniversaries of March 1, 2024, subject to the reporting person's continued service with the Issuer. This option was granted on March 1, 2024. The option is scheduled to vest with respect to 25% of the underlying ordinary shares on March 1, 2025 and the remaining 75% of the underlying ordinary shares shall vest in 12 equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer. Chief Legal Officer and Secretary /s/ Maiken Keson-Brookes 2024-03-04